ERVW-1 and myeloid sarcoma: Based on the present observations and on the preclinical efficacy of an anti-Env neutralizing monoclonal antibody in MS-like EAE animal models induced by HERV-W Env, as evoked above in this discussion, a humanized antibody is now to be evaluated in clinical trials with MS patients (Clinical Phase I has been achieved).